Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BODO Study of bosutinib step-in dosing in chronic phase chronic myeloid leukemia
2014-005531-13Phase 2Terminated
- Sponsor
- University of Bonn
- Start
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bosutinib in chronic myelogenous leukemia (CML), sponsored by University of Bonn. Primary endpoint: Rate of gastrointestinal toxicity within the first 6 months. Started Sep 2015; status: terminated.
02
Drugs
bosutinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2014-005531-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005531-13.